Rockville, United States
Rexahn Pharmaceuticals is a NY Stock Exchange listed biopharmaceutical company focusing on the development of targeted therapeutics for cancer treatment. Established in 2001, Rexahn's mission is to enhance the lives of cancer patients by creating next-generation therapies with increased efficacy and reduced side effects. Its products specifically target proteins implicated in cancer cell proliferation, indicating potential effectiveness against drug-resistant and difficult-to-treat cancers. Currently, the company has two product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and others in preclinical development, including RX-0201.
During its last investment round on 23 January 2019, the company secured an $8.60M Post-IPO Equity investment, demonstrating confidence from investors in its research and development initiatives. Rexahn's focus on addressing unmet medical needs in cancer treatment positions it as a promising player in the biotechnology and pharmaceutical industries. For further details on the company and its oncology programs, individuals can visit www.rexahn.com.
Radionetics Oncology
